{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:45Z","timestamp":1786998465969,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451-03-68\/2020-14\/ 200042"],"award-info":[{"award-number":["451-03-68\/2020-14\/ 200042"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ymgmr.2021.100822","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T10:24:32Z","timestamp":1637317472000},"page":"100822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Untreated PKU patients without intellectual disability: SHANK gene family as a candidate modifier"],"prefix":"10.1016","volume":"29","author":[{"given":"K.","family":"Klaassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Skakic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kecman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Drmanac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stojiljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2021.100822_bb0005","series-title":"The Online Metabolic and Molecular Basis of Inherited Disease","article-title":"Hyperphenylalaninemia: phenylalanine hydroxylase deficiency","author":"Scriver","year":"2008"},{"key":"10.1016\/j.ymgmr.2021.100822_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.26.1.1","article-title":"An evaluation of the treatment of phenylketonuria with diets low in phenylalanine","volume":"26","author":"Knox","year":"1960","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2021.100822_bb0015","article-title":"Metabolic control during the neonatal period in phenylketonuria: associations with childhood IQ","author":"Liemburg","year":"2021","journal-title":"Pediatr Res"},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100822_bb0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13023-018-0890-7","article-title":"Can untreated PKU patients escape from intellectual disability? A systematic review","volume":"13","author":"van Vliet","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100822_bb0025","first-page":"49","article-title":"Molecular genetics and genotype-based estimation of BH4-responsiveness in serbian PKU patients: spotlight on phenotypic implications of pL48S","volume":"9","author":"Djordjevic","year":"2013"},{"key":"10.1016\/j.ymgmr.2021.100822_bb0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0168-9525(99)01761-8","article-title":"Monogenic traits are not simple","volume":"15","author":"Scriver","year":"1999","journal-title":"Trends Genet."},{"key":"10.1016\/j.ymgmr.2021.100822_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/mgme.2000.3052","article-title":"Modifier genes convert \"simple\" mendelian disorders to complex traits","volume":"71","author":"Dipple","year":"2000","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100822_bb0040","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1086\/302938","article-title":"Phenotypes of patients with \u00bbsimple\u00ab mendelian disorders are complex traits: thresholds, modifiers and system dynamics","volume":"66","author":"Dipple","year":"2000","journal-title":"Am. J. Hum. Genet."},{"issue":"11","key":"10.1016\/j.ymgmr.2021.100822_bb0045","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/00004647-199811000-00004","article-title":"Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria","volume":"18","author":"Moller","year":"1998","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100822_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1005328717095","article-title":"Pathogenesis of different clinical outcomes in spite of identical genotypes and comparable blood phenylalanine concentrations in phenylketonurics","volume":"21","author":"Weglage","year":"1998","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100822_bb0055","article-title":"The rs113883650 variant of SLC7A5 (LAT1) gene may alter brain phenylalanine content in PKU","volume":"27","author":"Bik-Multanowski","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"Suppl 1","key":"10.1016\/j.ymgmr.2021.100822_bb0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2009.10.016","article-title":"Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses","volume":"99","author":"de Groot","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100822_bb0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10545-008-0946-2","article-title":"Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause?","volume":"32","author":"van Spronsen","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100822_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-4328(03)00075-5","article-title":"Beta-phenylpyruvate induces long-term neurobehavioral damage and brain necrosis in neonatal mice","volume":"143","author":"Gazit","year":"2003","journal-title":"Behav. Brain Res."},{"issue":"Suppl 2","key":"10.1016\/j.ymgmr.2021.100822_bb0075","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1007\/PL00014371","article-title":"The neuropathology of phenylketonuria: human and animal studies","volume":"159","author":"Huttenlocher","year":"2000","journal-title":"Eur. J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100822_bb0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11011-015-9763-0","article-title":"Phenylalanine induces oxidative stress and decreases the viability of rat astrocytes: possible relevance for the pathophysiology of neurodegeneration in phenylketonuria","volume":"31","author":"Preissler","year":"2016","journal-title":"Metab. Brain Dis."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100822_bb0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jnr.24598","article-title":"White matter disturbances in phenylketonuria: possible underlying mechanisms","volume":"99","author":"Ferreira","year":"2021","journal-title":"J. Neurosci. Res."},{"issue":"4 Pt 1","key":"10.1016\/j.ymgmr.2021.100822_bb0090","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1203\/01.pdr.0000203091.45988.8d","article-title":"Phenylalanine reduces synaptic density in mixed cortical cultures from mice","volume":"59","author":"H\u00f6rster","year":"2006","journal-title":"Pediatr. Res."},{"issue":"5","key":"10.1016\/j.ymgmr.2021.100822_bb0095","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1124\/mol.104.005983","article-title":"Differential modulation of glutamatergic transmission by 3,5-dibromo-L-phenylalanine","volume":"67","author":"Yarotskyy","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.ymgmr.2021.100822_bb0100","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10571-011-9693-2","article-title":"Oxidative stress in phenylketonuria: what is the evidence?","volume":"31","author":"Ribas","year":"2011","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.ymgmr.2021.100822_bb0105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1399-0004.2006.00650.x","article-title":"Molecular and phenotypic characteristics of patients with phenylketonuria in Serbia and Montenegro","volume":"70","author":"Stojiljkovic","year":"2006","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2021.100822_bb0110","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/cge.13093","article-title":"Genetic characterization of GSD I in serbian population revealed unexpectedly high incidence of GSD ib and 3 novel SLC37A4 variants","volume":"93","author":"Skakic","year":"2018","journal-title":"Clin. Genet."},{"issue":"5961","key":"10.1016\/j.ymgmr.2021.100822_bb0115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.1181498","article-title":"Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays","volume":"327","author":"Drmanac","year":"2010","journal-title":"Science"},{"issue":"7873","key":"10.1016\/j.ymgmr.2021.100822_bb0120","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ymgmr.2021.100822_bb0125","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymgmr.2021.100822_bb0130","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43561","article-title":"Human VPS13A is associated with multiple organelles and influences mitochondrial morphology and lipid droplet motility","volume":"8","author":"Yeshaw","year":"2019","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100822_bb0135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0896-6273(00)80809-0","article-title":"Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor\/PSD-95\/GKAP complex and cortactin","volume":"23","author":"Naisbitt","year":"1999","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.ymgmr.2021.100822_bb0140","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/hmg\/ddv620","article-title":"Exome arrays capture polygenic rare variant contributions to schizophrenia","volume":"25","author":"Richards","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.ymgmr.2021.100822_bb9046","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/ng.589","article-title":"Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation","volume":"42","author":"Berkel","year":"2010","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100822_bb9045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng1933","article-title":"Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders","volume":"39","author":"Durand","year":"2007","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.ymgmr.2021.100822_bb0145","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.3390\/nu11112572","article-title":"Untreated PKU patients without intellectual disability: what do they teach Us?","volume":"11","author":"van Vliet","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgmr.2021.100822_bb0150","article-title":"The genetic landscape and epidemiology of phenylketonuria","volume":"1:S0002\u20139297(20)","author":"Hillert","year":"2020","journal-title":"Am. J. Hum. Genet."},{"issue":"Suppl","key":"10.1016\/j.ymgmr.2021.100822_bb0155","article-title":"Undiagnosed phenylketonuria in parents of phenylketonuric patients, is it worthwhile to be checked?","volume":"110","author":"Wiedemann","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgmr.2021.100822_bb0160","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s10545-006-0285-0","article-title":"LAT1 gene variants\u2013potential factors influencing the clinical course of phenylketonuria","volume":"29","author":"Bik-Multanowski","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgmr.2021.100822_bb0165","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1046\/j.1471-4159.2002.00931.x","article-title":"ProSAP\/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease","volume":"81","author":"Boeckers","year":"2002","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100822_bb9047","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/dneu.22128","article-title":"The emerging role of SHANK genes in neuropsychiatric disorders","volume":"74","author":"Guilmatre","year":"2014","journal-title":"Dev. Neurobiol."},{"key":"10.1016\/j.ymgmr.2021.100822_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.102004","article-title":"Generation of two hiPSC lines from a patient with autism spectrum disorder harboring a 120 kb deletion in SHANK2 and two control lines from each parent","volume":"49","author":"Cristian","year":"2020","journal-title":"Stem Cell Res."},{"issue":"Pt B","key":"10.1016\/j.ymgmr.2021.100822_bb0175","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.pnpbp.2017.11.019","article-title":"SHANK genes in autism: defining therapeutic targets","volume":"84","author":"Mossa","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100822_bb0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1203\/PDR.0b013e31806772be","article-title":"Differential effects of phenylalanine on Rac1, Cdc42, and RhoA expression and activity in cultured cortical neurons","volume":"62","author":"Zhang","year":"2007","journal-title":"Pediatr. Res."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100822_bb0185","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/brain\/awh354","article-title":"Long-term changes in glutamatergic synaptic transmission in phenylketonuria","volume":"128","author":"Glushakov","year":"2005","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.ymgmr.2021.100822_bb0190","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.mp.4000976","article-title":"Specific inhibition of N-methyl-D-aspartate receptor function in rat hippocampal neurons by L-phenylalanine at concentrations observed during phenylketonuria","volume":"7","author":"Glushakov","year":"2002","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100822_bb0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jnr.10569","article-title":"L-phenylalanine selectively depresses currents at glutamatergic excitatory synapses","volume":"72","author":"Glushakov","year":"2003","journal-title":"J. Neurosci. Res."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100822_bb0200","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrn.2016.183","article-title":"SHANK proteins: roles at the synapse and in autism spectrum disorder","volume":"18","author":"Monteiro","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100822_bb0205","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ana.24349","article-title":"Protective variant for hippocampal atrophy identified by whole exome sequencing","volume":"77","author":"Nho","year":"2015","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100822_bb0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymgmr.2021.100822_bb0215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00692698","article-title":"Morphologic and histoanatomic observations of the brain in untreated human phenylketonuria","volume":"58","author":"Bauman","year":"1982","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.ymgmr.2021.100822_bb9048","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10545-006-0395-8","article-title":"Large neutral amino acids in the treatment of phenylketonuria (PKU)","volume":"29","author":"Matalon","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.ymgmr.2021.100822_bb0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug repurposing for rare diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.ymgmr.2021.100822_bb0225","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jnnp.2008.151175","article-title":"Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet","volume":"80","author":"Lee","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921001178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921001178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:53:38Z","timestamp":1762001618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426921001178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"alternative-id":["S2214426921001178"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100822","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Untreated PKU patients without intellectual disability: SHANK gene family as a candidate modifier","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100822"}}